Myasthenia Gravis Treatment Market to Witness Tremendous Growth, Expected to Surpass USD 3.1 Billion by 2032, Report
According to a new report published by Allied Market Research, titled, “Myasthenia Gravis Treatment Market,” The myasthenia gravis treatment market was valued at $1.7 billion in 2022, and is estimated to reach $3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032.
Prime determinants of growth
The global market for myasthenia gravis treatment is experiencing growth driven by rising demand for effective treatments, increasing prevalence of the disease, and advancements in novel drug research and development. However, the market growth is hindered by side effects associated with current treatments. Nonetheless, emerging markets present lucrative opportunities for market expansion during the forecast period.
Request Sample Copy of the Report: https://www.alliedmarketresearch.com/request-sample/A11194
North America to maintain its dominance by 2032
North America led the global myasthenia gravis treatment market in 2022, capturing nearly half of the revenue share and is projected to maintain its dominance throughout the forecast period. This growth is fueled by factors such as the high prevalence of myasthenia gravis, a growing diagnosis rate of autoimmune diseases, advanced healthcare infrastructure, and the presence of major pharmaceutical players offering innovative therapies.
Conversely, the Asia-Pacific region is anticipated to witness the fastest compound annual growth rate (CAGR) of 7.6% from 2023 to 2032. This growth can be attributed to the increasing incidence of autoimmune diseases, heightened awareness campaigns about autoimmune conditions and available treatments, as well as increased investments in the development of effective treatment options for myasthenia gravis.
Myasthenia Gravis Treatment Market Report Segmentation
| By Drug class |
|
| By Age group |
|
| By Distribution channel |
|
| By Region |
|
Recent Product Approval in Myasthenia Gravis Treatment Market
- In September 2022, Ultomiris (ravulizumab) received approval in Europe for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
- In April 2023, Global biotechnology leader CSL Behring received the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid).
Recent Acquisition in Myasthenia Gravis Treatment Market
- In April 2022, Grifols a global leader in plasma-derived medicines acquired Tiancheng (Germany) Pharmaceutical Holdings AG, a German company, specialized in innovative hematology and clinical immunology.
- In March 2021, Grifols a global healthcare company, acquired GigaGen Inc., a U.S. biotechnology company specialized in the early discovery and development of recombinant biotherapeutic medicines.
Do Purchase Enquiry– https://www.alliedmarketresearch.com/purchase-enquiry/A11194
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the myasthenia gravis medication market segments, current trends, estimations, and dynamics of the myasthenia gravis treatment market analysis from 2022 to 2032 to identify the prevailing myasthenia gravis treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the myasthenia gravis treatment medication market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the myasthenia gravis medication market players.
- The report includes the analysis of the regional as well as global myasthenia gravis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Takeaways
- By drug class, the intravenous immunoglobulin (IVIg) segment accounted for largest share in terms of revenue for myasthenia gravis treatment industry in 2022.
- By age group, the above 50 years segment accounted for largest share in terms of revenue for myasthenia gravis treatment industry in 2022.
- On the basis of distribution channel, the drug stores and retail pharmacies segment accounted for largest share in terms of revenue in 2022. However, online providers segment is anticipated to grow at the highest CAGR during the forecast period.
- Region wise, North America occupied the largest share in terms of revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Key Market Players
- Novartis AG
- Astellas Pharma Inc.
- Bausch Health Companies, Inc.
- F. Hoffmann-La Roche Ltd.
- Octapharma AG
- Zydus Lifesciences Limited
- AstraZeneca
- CSL Limited
- Grifols, S.A.
- Kedrion, SpA
Trending Reports in Healthcare Industry (Book Now with 10% Discount):
Chronic Kidney Disease Treatment Market https://www.alliedmarketresearch.com/chronic-kidney-disease-treatment-market-A107121
Ocular Drug Delivery Market https://www.alliedmarketresearch.com/ocular-drug-delivery-market
Editor Details
-
Company:
- The Wire Times
